Bristol-Myers Squibb Appoints Paul Biondi Senior Vice President, Head of Business Development
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Leerink Partners Remains Bullish on Five Prime Therapeutics (FPRX) Following announced Agreement with BMY
October 15, 2015 4:06 PM EDTLeerink Partners reiterated an Outperform rating on Five Prime Therapeutics (NASDAQ: FPRX) following an announced exclusive $1.74Bn license and collaboration agreement with Bristol-Myers Squibb Company (NYSE: BMY) for the development and commercialization of FPRXs CSF1R antibody... More
Bristol-Myers Squibb (BMY) Names New Business Development SVP
October 15, 2015 2:20 PM EDTBristol-Myers Squibb (NYSE: BMY) announced that Paul Biondi has been appointed senior vice president, head of Business Development and will report to Charlie Bancroft, chief financial officer. In this role, Biondi will lead the development of strategic partnerships and pursue scientific innovations across commercial, development, discovery and technology platforms to complement the companys internal R&D pipeline. Biondi most recently served as senior vice president, head of R&D Operations, Bristol-Myers Squibb.
Paul has established himself as a dynamic and collaborative leader at Bristol-Myers Squibb and made... More
